<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04544475</url>
  </required_header>
  <id_info>
    <org_study_id>19-01922</org_study_id>
    <nct_id>NCT04544475</nct_id>
  </id_info>
  <brief_title>A Randomized, Single Center Pilot Study Comparing Hyaluronic Acid to Vaginal Estrogen for Treatment of Genitourinary Syndrome of Menopause</brief_title>
  <official_title>A Randomized, Single Center Pilot Study Comparing Hyaluronic Acid to Vaginal Estrogen for Treatment of Genitourinary Syndrome of Menopause</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>JDS Therapeutics, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-hormonal alternatives for the treatment of genitourinary syndrome of menopause (GSM) are&#xD;
      needed. In this proposed trial, patients who are diagnosed with GSM will be randomized to&#xD;
      receive either a hyaluronic acid (HLA) vaginal insert or vaginal estrogen topical cream for 8&#xD;
      weeks. There will be a baseline visit and an 8 week follow up visit, at which points the&#xD;
      patient will undergo a detailed history and physical examination including a pelvic exam,&#xD;
      vaginal pH sampling, vaginal cell sample for microscopic analysis, and will fill out a&#xD;
      vulvovaginal symptom questionnaire (VSQ). These study arms will be analyzed to assess the&#xD;
      efficacy of HLA as compared to the gold standard of vaginal estrogen to treat GSM symptoms.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in VSQ Score</measure>
    <time_frame>Baseline, Week 8</time_frame>
    <description>The VSQ (Vulvovaginal Symptoms Questionnaire) is a 21-question survey developed in 2012 that specifically asks about GSM symptoms, their emotional impact, sexual impact, and life impact. Each question is scored from 0 (free of discomfort) to 3 (severe discomfort) The total score ranges from 0 (symptom-free in all areas) to 63 (severe discomfort in all areas) - the higher the score, the more severe the discomfort.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in VMI</measure>
    <time_frame>Baseline, Week 8</time_frame>
    <description>VMI (Vaginal Maturation Index) is the microscopic analysis of vaginal tissue that assigns the percentage to the amount of parabasal, intermediate, and squamous cells visualized that add up to 100%. Only the % of squamous cells will be reported in this study since that is most closely correlated with hormonal influence on the vaginal tissue. Vaginal tissue sample will be obtained via scraping for VMI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Vaginal pH</measure>
    <time_frame>Baseline, Week 8</time_frame>
    <description>Pelvic samples will be collected to test vaginal pH</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in VAS Score</measure>
    <time_frame>Baseline, Week 8</time_frame>
    <description>VAS (Visual Analog Scale) score will be reported for dyspareunia, itching, and dryness. VAS is a visual scale attempting to capture the intensity of a symptom. For each symptom, the score ranges from 0-10. The higher the score, the more severe the symptom. Each symptom will be reported separately.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaginal Rugal Folds</measure>
    <time_frame>Week 8</time_frame>
    <description>During the pelvic exam, the investigator will note the presence of vaginal rugal folds. This outcome measure is a binary variable (present or not present) and single/categorical endpoint -- it will be reported as the percentage of patients with rugal folds divided by the cohort size.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Genitourinary Syndrome of Menopause (GSM)</condition>
  <arm_group>
    <arm_group_label>Investigational</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Revaree</intervention_name>
    <description>Hyaluronic Acid Vaginal Insert (Revaree). A 2g vaginal insert that contains 5mg of HLA sodium salt and a base of semi-synthetic glycerides. It is an insert that does not require an applicator and should be placed in the vagina while laying down twice weekly.</description>
    <arm_group_label>Investigational</arm_group_label>
    <other_name>HLA Vaginal Insert</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estrace</intervention_name>
    <description>Vaginal estrogen cream, estradiol: 100mcg</description>
    <arm_group_label>Standard of Care</arm_group_label>
    <other_name>Vaginal estrogen cream</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Postmenopausal status as defined by amenorrhea for &gt;12 months or history of bilateral&#xD;
             salpingo-oophrectomy or if the patient has had a hysterectomy and menopausal symptoms&#xD;
             for &gt;1 year or FSH &gt; 40&#xD;
&#xD;
          2. Symptoms of GSM&#xD;
&#xD;
          3. Negative Pap smear within two years&#xD;
&#xD;
          4. Capable of giving informed consent&#xD;
&#xD;
          5. Ambulatory&#xD;
&#xD;
          6. Capable and willing to follow all study-relation procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Use of any HRT (systemic or local) or raloxifene within six weeks of proposed start&#xD;
             date&#xD;
&#xD;
          2. History of estrogen-sensitive tumor&#xD;
&#xD;
          3. Undiagnosed vaginal bleeding in the past 12 months&#xD;
&#xD;
          4. History of thromboembolic event&#xD;
&#xD;
          5. Currently have or have had liver problem&#xD;
&#xD;
          6. Bleeding disorder&#xD;
&#xD;
          7. Impaired mental status&#xD;
&#xD;
          8. Prior pelvic irradiation&#xD;
&#xD;
          9. Active vaginal infection&#xD;
&#xD;
         10. Any medical reason the investigator deems incompatible with treatment with vaginal&#xD;
             estrogen&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lila Nachtigall, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU Langone Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Surbhi Agrawal, MD</last_name>
    <phone>(646) 825-6300</phone>
    <email>Surbhi.agrawal@nyulangone.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christina Escobar, MD</last_name>
    <phone>(646) 825-6300</phone>
    <email>Christina.escobar@nyulangone.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>NYU Langone Health</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Surbhi Agrawal, MD</last_name>
      <phone>646-825-6300</phone>
      <email>Surbhi.agrawal@nyulangone.org</email>
    </contact>
    <contact_backup>
      <last_name>Christina Escobar, MD</last_name>
      <phone>(646) 825-6300</phone>
      <email>Christina.escobar@nyulangone.org</email>
    </contact_backup>
    <investigator>
      <last_name>Lila Nachtigall, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Surbhi Agrawal, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christina Escobar, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 4, 2020</study_first_submitted>
  <study_first_submitted_qc>September 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2020</study_first_posted>
  <last_update_submitted>August 10, 2021</last_update_submitted>
  <last_update_submitted_qc>August 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estrogens</mesh_term>
    <mesh_term>Estradiol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices) will be shared upon reasonable request.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>The data will be become available beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.</ipd_time_frame>
    <ipd_access_criteria>The investigator who proposed to use the data upon reasonable request. Requests should be directed to Surbhi.agrawal@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

